Meeting
2023 ASCO Annual Meeting
Association of single-click radiomic classifier with response and prognosis in non-small cell lung cancers (NSCLC) treated with immune checkpoint inhibitors.
Authors
Amogh Hiremath
Picture Health, Cleveland, OH
Amogh Hiremath , Haojia Li , Allison Clement , Amit Gupta , Vamsidhar Velcheti , Anant Mababhushi , Nathaniel Braman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8574)
DOI
10.1200/JCO.2023.41.16_suppl.8574
Abstract #
8574
Poster Bd #
201
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non–small cell lung cancer.
First Author: Changhee Park
Poster
2023 ASCO Annual Meeting
Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.
First Author: Chiharu Sako
Poster
2023 ASCO Annual Meeting
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
First Author: Tämer El Saadany